Therapeutics, Placebo, and the Importance of Hard Outcomes in Irritable Bowel Syndrome Research

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by a combination of recurrent abdominal pain and altered bowel habits.1 It is an international source of disease burden and affects an estimated 5% –10% of the adult population.1 It is also an important source of decreased quality of life, healthcare costs, and missed days of work and school.2,3
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research